A Canadian multicenter study of three fixed doses of controlled-release ipsapirone in outpatients with moderate to severe major depression.

@article{Lapierre1998ACM,
  title={A Canadian multicenter study of three fixed doses of controlled-release ipsapirone in outpatients with moderate to severe major depression.},
  author={Yvon D. Lapierre and Peter Silverstone and R T Reesal and Bishan Saxena and Patricia H. Turner and David Bakish and Joanne Plamondon and Praloran Vincent and Ronald A. Remick and Cara D. L. Kroft and Richard Payeur and David Rosales and Ricky Lam and Monica Bologa},
  journal={Journal of clinical psychopharmacology},
  year={1998},
  volume={18 4},
  pages={
          268-73
        }
}
Ipsapirone, an azapirone with 5-hydroxytryptamine (5-HT1A) partial agonist activity, has been shown in preliminary studies to be effective in the treatment of major depressive disorder. This 8-week, randomized, double-blind study compared the efficacy, safety, and tolerability of three fixed doses of controlled-release ipsapirone (10-, 30-, and 50-mg dose once daily) with placebo in 410 patients with moderate to severe major depression (Hamilton Rating Scale for Depression [HAM-D] score > or… CONTINUE READING